Physician profile
Audrey Hengen
NPI 1699348904
$3,656.72
in general payments reported to CMS, 2019-2025
29 companies · $579 in 2025
The $579 reported for 2025 was more than what 75% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.51 · 2022: $675 · 2023: $1,513 · 2024: $800 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,891.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $675.51 | 2022-2024 | Watchman Access System, Rhythmia Mapping System |
| Impulse Dynamics (USA) INC. | $386.46 | 2022-2023 | Optimizer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.52 | 2021-2025 | Jardiance |
| Cvrx, INC. | $222.06 | 2023 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $207.97 | 2021-2025 | Wainua, Farxiga, Lokelma |
| Merck Sharp & Dohme LLC | $207.01 | 2022-2025 | Verquvo |
| Medtronic, INC. | $202.77 | 2023 | Onyx Frontier, Micra |
| Pfizer INC. | $178.68 | 2022-2025 | |
| Amgen INC. | $159.86 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $156.09 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $149.91 | 2022-2025 | |
| Novo Nordisk INC | $124.81 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $115.83 | 2021-2023 | Arcalyst |
| Edwards Lifesciences Corporation | $88.51 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Scpharmaceuticals INC. | $80.77 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $72.70 | 2024-2025 | |
| Baxter Healthcare | $52.09 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Bridgebio Pharma, INC. | $51.55 | 2025 | Attruby |
| Kiniksa Pharmaceuticals International, Plc | $46.46 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $40.37 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $31.16 | 2024 | |
| Alnylam Pharmaceuticals INC. | $23.65 | 2024 | Amvuttra |
| Genzyme Corporation | $22.62 | 2023 | |
| Atricure, INC. | $21.91 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax, Synergy Ablation System |
| Cleerly, INC. | $21.49 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Abiomed | $20.32 | 2024 | Impella |
| Regeneron Healthcare Solutions, INC. | $20.06 | 2024 | Evkeeza |
| Philips North America LLC | $18.21 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Bardy Diagnostics, INC. | $17.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Hengen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.